tbuckley/cabot-search huggingface dataset:
Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells
Authors: King L. Hung, Iana Meitlis, Malika Hale, Chun-Yu Chen, Swati Singh, Shaun W. Jackson, Carol H. Miao, Iram F. Khan, David J. Rawlings, Richard G. James
Journal: Molecular Therapy (2017)
Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes within fibrotic foci of tumor stroma (FF-TILs)
Authors: S. Kashiwagi, Y. Asano, W. Goto, K. Takada, T. Takashima, T. Morisaki, S. Noda, N. Onoda, K. Hirakawa, M. Ohira
Journal: Annals of Oncology (2017)
P3.02b-086 ASP8273 Tolerability and Antitumor Activity in TKI-Naïve Japanese Subjects with EGFRmut+ NSCLC: Preliminary Results
Authors: Makoto Nishio, Koichi Azuma, Hidetoshi Hayashi, Toyoaki Hida, Akira Inoue, Yasuo Iwamoto, Satoshi Ikeda, Katsuyuki Kiura, Miyako Satouchi, Shunichi Sugawara, Koji Takeda, Desai Bhardwaj, Anne Keating, Kanji Komatsu, Maiko Morishita, Kentaro Takeda, Satoshi Morita, Masahiro Fukuoka, Kazuhiko Nakagawa
Journal: Journal of Thoracic Oncology (2017)
Association Between Wait Time and 30-Day Mortality in Adults Undergoing Hip Fracture Surgery
Authors: Daniel Pincus, Bheeshma Ravi, David Wasserstein, Anjie Huang, J. Michael Paterson, Avery B. Nathens, Hans J. Kreder, Richard J. Jenkinson, Walter P. Wodchis
Journal: JAMA (2017)

Although wait times for hip fracture surgery have been linked to mortality and are being used as quality-of-care indicators worldwide, controversy exists about the duration of the wait that leads to complications.To use population-based wait-time data to identify the optimal time window in which to conduct hip fracture surgery before the risk of complications increases.Population-based, retrospective cohort study of adults undergoing hip fracture surgery between April 1, 2009, and March 31, 2014, at 72 hospitals in Ontario, Canada. Risk-adjusted restricted cubic splines modeled the probability of each complication according to wait time. The inflection point (in hours) when complications began to increase was used to define early and delayed surgery. To evaluate the robustness of this definition, outcomes among propensity-score matched early and delayed surgical patients were compared using percent absolute risk differences (RDs, with 95% CIs).Time elapsed from hospital arrival to surgery (in hours).Mortality within 30 days. Secondary outcomes included a composite of mortality or other medical complications (myocardial infarction, deep vein thrombosis, pulmonary embolism, and pneumonia).Among 42 230 patients with hip fracture (mean [SD] age, 80.1 years [10.7], 70.5% women) who met study entry criteria, overall mortality at 30 days was 7.0%. The risk of complications increased when wait times were greater than 24 hours, irrespective of the complication considered. Compared with 13 731 propensity-score matched patients who received surgery earlier, 13 731 patients who received surgery after 24 hours had a significantly higher risk of 30-day mortality (898 [6.5%] vs 790 [5.8%]; % absolute RD, 0.79; 95% CI, 0.23-1.35) and the composite outcome (1680 [12.2%]) vs 1383 [10.1%]; % absolute RD, 2.16; 95% CI, 1.43-2.89).Among adults undergoing hip fracture surgery, increased wait time was associated with a greater risk of 30-day mortality and other complications. A wait time of 24 hours may represent a threshold defining higher risk.
Thioesterase-mediated control of cellular calcium homeostasis enables hepatic ER stress
Authors: Baran A. Ersoy, Kristal M. Maner-Smith, Yingxia Li, Ipek Alpertunga, David E. Cohen
Journal: Journal of Clinical Investigation (2017)

The incorporation of excess saturated free fatty acids (SFAs) into membrane phospholipids within the ER promotes ER stress, insulin resistance, and hepatic gluconeogenesis. Thioesterase superfamily member 2 (Them2) is a mitochondria-associated long-chain fatty acyl-CoA thioesterase that is activated upon binding phosphatidylcholine transfer protein (PC-TP). Under fasting conditions, the Them2/PC-TP complex directs saturated fatty acyl-CoA toward β-oxidation. Here, we showed that during either chronic overnutrition or acute induction of ER stress, Them2 and PC-TP play critical roles in trafficking SFAs into the glycerolipid biosynthetic pathway to form saturated phospholipids, which ultimately reduce ER membrane fluidity. The Them2/PC-TP complex activated ER stress pathways by enhancing translocon-mediated efflux of ER calcium. The increased cytosolic calcium, in turn, led to the phosphorylation of calcium/calmodulin-dependent protein kinase II, which promoted both hepatic insulin resistance and gluconeogenesis. These findings delineate a mechanistic link between obesity and insulin resistance and establish the Them2/PC-TP complex as an attractive target for the management of hepatic steatosis and insulin resistance.
Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug–Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients
Authors: Bodine P.S. Belderbos, Sander Bins, Roelof W.F. van Leeuwen, Esther Oomen-de Hoop, Nelly van der Meer, Peter de Bruijn, Paul Hamberg, Esther N.M. Overkleeft, Wendy M. van der Deure, Martijn P. Lolkema, Ronald de Wit, Ron H.J. Mathijssen
Journal: Clinical Cancer Research (2017)

Abstract Purpose: In ongoing clinical research on metastatic castration-resistant prostate cancer (mCRPC) treatment, the potential enhanced efficacy of the combination of taxanes with AR-targeted agents, that is, enzalutamide and abiraterone, is currently being explored. Because enzalutamide induces the CYP3A4 enzyme and taxanes are metabolized by this enzyme, a potential drug–drug interaction needs to be investigated. Experimental Design: Therefore, we performed a pharmacokinetic cross-over study in mCRPC patients who were scheduled for treatment with cabazitaxel Q3W (25 mg/m2). Patients were studied for three consecutive cabazitaxel cycles. Enzalutamide (160 mg once daily) was administered concomitantly after the first cabazitaxel cycle, during 6 weeks. Primary endpoint was the difference in mean area under the curve (AUC) between the first (cabazitaxel monotherapy) and third cabazitaxel cycle, when enzalutamide was added. Results: A potential clinically relevant 22% (95% CI, 9%–34%; P = 0.005) reduction in cabazitaxel exposure was found with concomitant enzalutamide use. The geometric mean AUC0–24h of cabazitaxel was 181 ng*h/mL (95% CI, 150–219 ng*h/mL) in cycle 3 and 234 ng*h/mL (95% CI, 209–261 ng*h/mL) in cycle 1. This combination did not result in excessive toxicity, whereas PSA response was promising. Conclusions: We found a significant decrease in cabazitaxel exposure when combined with enzalutamide. In an era of clinical trials on combination strategies for mCRPC, it is important to be aware of clinically relevant drug–drug interactions. Because recent study results support the use of a lower standard cabazitaxel dose of 20 mg/m2, the clinical relevance of this interaction may be substantial, because the addition of enzalutamide may result in subtherapeutic cabazitaxel exposure. Clin Cancer Res; 24(3); 541–6. ©2017 AACR.
Association between non-alcoholic fatty liver disease and cancer incidence rate
Authors: Gi-Ae Kim, Han Chu Lee, Jaewon Choe, Min-Ju Kim, Min Jung Lee, Hye-Sook Chang, In Young Bae, Hong-Kyu Kim, Jihyun An, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim
Journal: Journal of Hepatology (2017)
Hépatite et VIH dans les prisons d’Irlande du Nord : une étude croisée
Authors: K Danis, L Doherty, M McCartney, J McCarrol, H Kennedy
Journal: Eurosurveillance (2007)

Une etude a ete conduite dans les prisons d’Irlande du Nord (IN) afin (i) de determiner la prevalence des virus transmissibles par le sang parmi les codetenus, et (ii) d’evaluer l’etendue des comportements a risques auto-declares. Les trois prisons d’IN ont ete incluses dans l’etude. Les variables utilises etaient (i) les anticorps anti-VHC, l’antigene VHB, et VIH, et (ii) les comportements a risques auto-declares. Cinq prisonniers (0,75%) presentaient une serologie positive pour le VHB, sept (1,1%) pour le VHC et aucun pour le VIH. Onze pour cent ont declare avoir utilise des drogues injectables. Parmi eux, 20% ont commence en prison et 12% ont partage le materiel d’injection en prison. Deux pour cent etaient vaccines contre le VHB. Les drogues injectables etaient associees a l’infection par le VHC (ratio de prevalence ajuste=5,2 ; 95% IC 0,9-16) et le VHB (ratio de prevalence ajuste=4,1; 95% IC 0,7-23). La faible prevalence des virus transmissibles par le sang dans les prisons d’IN ne correspond pas aux resultats des etudes menees dans d’autres pays, refletant probablement la situation sociopolitique unique de l’Irlande du Nord. Des pratiques a haut risque existent, en depit de la conscience des risques de transmission des virus dans les prisons. La prevention des comportements a risque et de la transmission des infections dans les prisons est un defi pour les services sanitaires du Royaume-Uni.
Antipsychotic Drug Prescribing In Nursing Homes—Reply
Authors: Jerry H. Gurwitz, Alice Bonner, Donald M. Berwick
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer
Authors: Xuxu Sun, Sam C. Wang, Yonglong Wei, Xin Luo, Yuemeng Jia, Lin Li, Purva Gopal, Min Zhu, Ibrahim Nassour, Jen-Chieh Chuang, Thomas Maples, Cemre Celen, Liem H. Nguyen, Linwei Wu, Shunjun Fu, Weiping Li, Lijian Hui, Feng Tian, Yuan Ji, Shuyuan Zhang, Mahsa Sorouri, Tae Hyun Hwang, Lynda Letzig, Laura James, Zixi Wang, Adam C. Yopp, Amit G. Singal, Hao Zhu
Journal: Cancer Cell (2017)
Improved heart repair upon myocardial infarction: Combination of magnetic nanoparticles and tailored magnets strongly increases engraftment of myocytes
Authors: Annika Ottersbach, Olga Mykhaylyk, Alexandra Heidsieck, Dietmar Eberbeck, Sarah Rieck, Katrin Zimmermann, Martin Breitbach, Britta Engelbrecht, Tobias Brügmann, Michael Hesse, Armin Welz, Philipp Sasse, Daniela Wenzel, Christian Plank, Bernhard Gleich, Michael Hölzel, Wilhelm Bloch, Alexander Pfeifer, Bernd K. Fleischmann, Wilhelm Roell
Journal: Biomaterials (2017)
Abstract 15627: Identification of Cardiovascular Risk Factors Associated With Bone Marrow Cell Subsets in Patients With STEMI: A Biorepository Evaluation From the CCTRN TIME and LateTIME Clinical Trials
Authors: Ariadna Contreras, Aaron F Orozco, Robert C Schutt, Micheline M Resende, Luiz Sampaio, John P Cooke, Aruni Bhatnagar, Roberto Bolli, Michelle Cohen, James T Willerson, Lem Moyé, Doris A Taylor
Journal: Circulation (2015)

Objective: Results from several randomized, controlled cell therapy trials suggest that the use of autologous bone marrow mononuclear cells (BMMNCs) results in only modest benefits in patients with ST-segment elevation myocardial infarction (STEMI). However, the patients in these trials had varying combinations of underlying cardiovascular risk factors (CVRFs) and comorbidities. The autologous BMMNC product administered to each patient was unique. Based on our previous findings, the purpose of this study was to identify potential associations between specific CVRFs and BMMNC subsets in patients with STEMI. Methods: This study evaluated a cohort of patients with STEMI who were enrolled in either the CCTRN TIME or LateTIME trials and underwent BMMNC or placebo treatment (N=139). Flow cytometric analysis targeting phenotypic markers (eg, CD45, CD14, CD11b, CD3, CD19, CD31, and CD34) was used to assess the frequency of BMMNC subsets at baseline. The GRACE ACS Risk Score 2.0 - 3 year death (GRS) was used to stratify patients according to cardiovascular risk (low: GRS &lt;12%, moderate: GRS 12-30%, high: GRS &gt;30%). Multivariable models were then applied to assess relationships between BMMNC subsets and CVRFs, including age, smoking, hypertension, hyperlipidemia, and sex. Results: Patients were grouped as low GRS (n=69, 49.6%), moderate GRS (n=49, 35.3%), and high GRS (n=21, 15.1%). Patients with a high GRS had significantly lower frequencies of CD45+CD31+ cells than those with a low GRS (35.6% vs 40.3%, respectively, P=0.041). In multivariable analyses, age was inversely associated with the frequencies of CD34+ (P=0.011) and CD45+CD31+ (P=0.001) cells, and smoking was associated with a decrease in CD45+CD31+ cells (P=0.022). In addition, higher frequencies of CD11b+ cells were associated with hypertension (P=0.010) and hyperlipidemia (P=0.029). In contrast, the CD11b+ cell frequency was less in females (P=0.005). Conclusions: This study identified associations between specific CVRFs and BMMNC subsets. These associations may contribute to the heterogeneity of the cell product received. Thus, differences in patients’ comorbidities should be considered when designing future autologous cell therapy trials.
Response to: ‘Cardiovascular effects of hydroxychloroquine: a systematic review and meta-analysis’ by Mathieu <i>et al</i>
Authors: Charlotte Hua, Claire Rempenault, Bernard Combe
Journal: Annals of the Rheumatic Diseases (2017)

In their letter to the editor, Mathieu1 and colleagues provide information that reinforce the conclusions of our recent paper.2 3 We appreciate their interest in our study and complement the authors for their systematic review and meta-analysis of cardiovascular (CV) effects of hydroxychloroquine (HCQ) in rheumatoid arthritis (RA), lupus and other diseases.

In our study, we have chosen to focus only on RA for homogeneity reasons and because we think that demonstration of a positive influence of …
Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument: The PSC PRO
Authors: Zobair M. Younossi, Arian Afendy, Maria Stepanova, Andrei Racila, Fatema Nader, Rachel Gomel, Ricky Safer, William R. Lenderking, Anne Skalicky, Leah Kleinman, Robert P. Myers, G. Mani Subramanian, John G. McHutchison, Cynthia Levy, Christopher L. Bowlus, Kris Kowdley, Andrew J. Muir
Journal: Hepatology (2017)

Primary sclerosing cholangitis (PSC) is a chronic liver disease associated with inflammation and biliary fibrosis that leads to cholangitis, cirrhosis, and impaired quality of life. Our objective was to develop and validate a PSC‐specific patient‐reported outcome (PRO) instrument. We developed a 42‐item PSC PRO instrument that contains two modules (Symptoms and Impact of Symptoms) and conducted an external validation. Reliability and validity were evaluated using clinical data and a battery of other validated instruments. Test‐retest reliability was assessed in a subgroup of patients who repeated the PSC PRO after the first administration. One hundred two PSC subjects (44 ± 13 years; 32% male, 74% employed, 39% with cirrhosis, 14% with a history of decompensated cirrhosis, 38% history of depression, and 68% with inflammatory bowel disease [IBD]) completed PSC PRO and other PRO instruments (Short Form 36 V2 [SF‐36], Chronic Liver Disease Questionnaire [CLDQ], Primary Biliary Cholangitis – 40 [PBC‐40], and five dimensions [5‐D Itch]). PSC PRO demonstrated excellent internal consistency (Cronbach alphas, 0.84‐0.94) and discriminant validity (41 of 42 items had the highest correlations with their own domains). There were good correlations between PSC PRO domains and relevant domains of SF‐36, CLDQ, and PBC‐40 (R = 0.69‐0.90; all P < 0.0001), but lower (R = 0.31‐0.60; P < 0.001) with 5‐D Itch. Construct validity showed that PSC PRO can differentiate patients according to the presence and severity of cirrhosis and history of depression (P < 0.05), but not by IBD (P > 0.05). Test‐retest reliability was assessed in 53 subjects who repeated PSC PRO within a median (interquartile range) of 37 (27‐47) days. There was excellent reliability for most domains with intraclass correlations (0.71‐0.88; all P < 0.001). Conclusion: PSC PRO is a self‐administered disease‐specific instrument developed according to U.S. Food and Drug Administration guidelines. This preliminary validation study suggests good psychometric properties. Further validation of the instrument in a larger and more diverse sample of PSC patients is needed. (Hepatology 2018;68:155‐165).
Emerging infections—an increasingly important topic: review by the Emerging Infections Task Force
Authors: E. Petersen, N. Petrosillo, M. Koopmans, N. Beeching, A. Di Caro, E. Gkrania-Klotsas, A. Kantele, R. Kohlmann, M. Koopmans, P.-L. Lim, A. Markotic, R. López-Vélez, L. Poirel, J.W.A. Rossen, Y. Stienstra, M. Storgaard
Journal: Clinical Microbiology and Infection (2017)
Sorveglianza di salmonella: risultati ottenuti e obiettivi futuri
Authors: W van Pelt
Journal: Eurosurveillance (1999)

Questo numero speciale di Eurosurveillance e dedicato al progresso della rete Enter-net nella sorveglianza e nella gestione dei focolai epidemici di salmonellosi umana in Europa. Questa rete ha istituito un archivio internazionale, che viene aggiornato frequentemente, e una collaborazione tra esperti che ha permesso di effettuare interventi risolutivi in Europa. L'articolo della Repubblica Ceca su Salmonella typhimurium multiresistente ai farmaci mostra l'importanza del recente allargamento del programma, con l'introduzione della resistenza antimicrobica della salmonellosi e l'ampliamento della rete per includere anche altri paesi europei.
The Neurodevelopmental Basis of Early Childhood Disruptive Behavior: Irritable and Callous Phenotypes as Exemplars
Authors: Lauren S. Wakschlag, Susan B. Perlman, R. James Blair, Ellen Leibenluft, Margaret J. Briggs-Gowan, Daniel S. Pine
Journal: American Journal of Psychiatry (2017)

The arrival of the Journal's 175th anniversary occurs at a time of recent advances in research, providing an ideal opportunity to present a neurodevelopmental roadmap for understanding, preventing, and treating psychiatric disorders. Such a roadmap is particularly relevant for early-childhood-onset neurodevelopmental conditions, which emerge when experience-dependent neuroplasticity is at its peak. Employing a novel developmental specification approach, this review places recent neurodevelopmental research on early childhood disruptive behavior within the historical context of the Journal. The authors highlight irritability and callous behavior as two core exemplars of early disruptive behavior. Both phenotypes can be reliably differentiated from normative variation as early as the first years of life. Both link to discrete pathophysiology: irritability with disruptions in prefrontal regulation of emotion, and callous behavior with abnormal fear processing. Each phenotype also possesses clinical and predictive utility. Based on a nomologic net of evidence, the authors conclude that early disruptive behavior is neurodevelopmental in nature and should be reclassified as an early-childhood-onset neurodevelopmental condition in DSM-5. Rapid translation from neurodevelopmental discovery to clinical application has transformative potential for psychiatric approaches of the millennium. [AJP at 175: Remembering Our Past As We Envision Our Future November 1938: Electroencephalographic Analyses of Behavior Problem Children Herbert Jasper and colleagues found that brain abnormalities revealed by EEG are a potential causal factor in childhood behavioral disorders. (Am J Psychiatry 1938; 95:641–658)]
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice
Authors: Edoardo Giovanni Giannini, Laura Bucci, Francesca Garuti, Matteo Brunacci, Barbara Lenzi, Matteo Valente, Eugenio Caturelli, Giuseppe Cabibbo, Fabio Piscaglia, Roberto Virdone, Martina Felder, Francesca Ciccarese, Francesco Giuseppe Foschi, Rodolfo Sacco, Gianluca Svegliati Baroni, Fabio Farinati, Gian Lodovico Rapaccini, Andrea Olivani, Antonio Gasbarrini, Maria Di Marco, Filomena Morisco, Marco Zoli, Alberto Masotto, Franco Borzio, Luisa Benvegnù, Fabio Marra, Antonio Colecchia, Gerardo Nardone, Mauro Bernardi, Franco Trevisani
Journal: Hepatology (2017)

The Barcelona Clinic Liver Cancer (BCLC) advanced stage (BCLC C) of hepatocellular carcinoma (HCC) includes a heterogeneous population, where sorafenib alone is the recommended treatment. In this study, our aim was to assess treatment and overall survival (OS) of BCLC C patients subclassified according to clinical features (performance status [PS], macrovascular invasion [MVI], extrahepatic spread [EHS] or MVI + EHS) determining their allocation to this stage. From the Italian Liver Cancer database, we analyzed 835 consecutive BCLC C patients diagnosed between 2008 and 2014. Patients were subclassified as: PS1 alone (n = 385; 46.1%), PS2 alone (n = 146; 17.5%), MVI (n = 224; 26.8%), EHS (n = 51; 6.1%), and MVI + EHS (n = 29; 3.5%). MVI, EHS, and MVI + EHS patients had larger and multifocal/massive HCCs and higher alpha‐fetoprotein (AFP) levels than PS1 and PS2 patients. Median OS significantly declined from PS1 (38.6 months) to PS2 (22.3 months), EHS (11.2 months), MVI (8.2 months), and MVI + EHS (3.1 months; P &lt; 0.001). Among MVI patients, OS was longer in those with peripheral than with central (portal trunk) MVI (11.2 vs. 7.1 months; P = 0.005). The most frequent treatments were: curative approaches in PS1 (39.7%), supportive therapy in PS2 (41.8%), sorafenib in MVI (39.3%) and EHS (37.3%), and best supportive care in MVI + EHS patients (51.7%). Independent prognostic factors were: Model for End‐stage Liver Disease score, Child‐Pugh class, ascites, platelet count, albumin, tumor size, MVI, EHS, AFP levels, and treatment type. Conclusion: BCLC C stage does not identify patients homogeneous enough to be allocated to a single stage. PS1 alone is not sufficient to include a patient into this stage. The remaining patients should be subclassified according to PS and tumor features, and new patient‐tailored therapeutic indications are needed. (H epatology 2018;67:1784‐1796).
Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients
Authors: K. Au, R.K. Ngan, A.W. Ng, D.M. Poon, W. Ng, V.H. Lee, A.W. Lee, A.C. Cheng, H. Tam
Journal: Annals of Oncology (2017)
MECA79 positive high endothelial venule density (HEV) correlates with clinical outcomes in upper tract urothelial carcinoma patients treated with radical nephroureterectomy
Authors: Y. Hashimoto, T. Yoneyama, H. Yamamoto, S. Hatakeyama, T. Yoneyama, T. Koie, C. Ohyama
Journal: Annals of Oncology (2017)
Efficacy and safety of tribendimidine versus praziquantel against Opisthorchis viverrini in Laos: an open-label, randomised, non-inferiority, phase 2 trial
Authors: Somphou Sayasone, Jennifer Keiser, Isabel Meister, Youthanavanh Vonghachack, Syda Xayavong, Kanpaseuth Senggnam, Khampheng Phongluxa, Jan Hattendorf, Peter Odermatt
Journal: The Lancet Infectious Diseases (2017)